Ohr Pharma's Eye Drug Fails in Mid-Stage Study, Shares PlungeOhr Pharma's Eye Drug Fails in Mid-Stage Study, Shares Plunge

Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares plunging 64 percent in premarket trading on Friday. Reuters Health Information
Source: Medscape Ophthalmology Headlines - Category: Opthalmology Tags: Ophthalmology News Source Type: news